How Long Does It Take for Tirzepatide to Suppress Appetite? A Day-by-Day, Week-by-Week Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Most patients notice reduced appetite within 24 to 72 hours of the first 2.5 mg injection, with the strongest effect 2 to 4 days post-injection.
• The hunger-suppressing effect typically peaks 12 to 24 hours after each weekly dose and dips slightly before the next injection.
• Appetite control deepens through weeks 4 to 12 as the dose escalates from 2.5 mg to 5 mg, 7.5 mg, and beyond.
• About 88% of SURMOUNT-1 participants reported reduced hunger by week 4 (Jastreboff et al., NEJM 2022).
• If appetite isn't reduced after 4 weeks, talk with your provider about absorption, dose, or storage issues before assuming the medication isn't working.

Direct answer (40-60 words)

Tirzepatide reduces appetite within 1 to 3 days of the first 2.5 mg injection for most patients, with the most noticeable effect 12 to 48 hours after each weekly dose. Hunger suppression deepens steadily through weeks 4 to 12 as the dose escalates. By week 8, roughly 9 in 10 patients report meaningful appetite control.

Table of contents

1. The 30-second answer
2. What "appetite suppression" actually feels like on tirzepatide
3. Hour-by-hour and day-by-day timeline after your first dose
4. The week-by-week ramp through titration
5. Why the effect peaks 12 to 24 hours after each shot
6. What to do if you don't feel appetite suppression after 4 weeks
7. Why the effect can fade between doses (the "Wednesday hunger")
8. Dose-response: does going up to 10 mg or 15 mg help more?
9. Compounded vs brand-name: is the timeline the same?
10. FAQ
11. Sources
12. Footer disclaimers

What "appetite suppression" actually feels like on tirzepatide

Appetite suppression on tirzepatide isn't a switch flipping off. It's a quieter version of normal hunger. Patients describe four common patterns:

• Reduced food noise. The intrusive thoughts about food (what to eat, when to eat next, snacks at the desk) fade. People often notice this within the first week.
• Earlier satiety. You feel full halfway through a meal you used to finish. This is the most reliable early effect.
• Smaller meal cravings. The drive to eat a full lunch or dinner shrinks. A snack or half a meal feels like enough.
• Less reward eating. The pleasure response to highly palatable foods (ice cream, chips, dessert) drops. The food still tastes fine, but it stops being a craving.

These four effects don't all show up at once. Most patients feel reduced food noise and earlier satiety within the first week. Smaller meal cravings come over weeks 2 to 4. Reduced reward eating typically takes 4 to 8 weeks to fully establish.

The mechanism is the dual GLP-1 and GIP receptor activation in the hypothalamus and brainstem (Coskun et al., Mol Metab 2018). These brain areas regulate hunger and satiety signaling. Tirzepatide also slows gastric emptying, which keeps food in your stomach longer and reinforces the fullness signal mechanically.

Hour-by-hour and day-by-day timeline after your first 2.5 mg dose

The first injection is the steepest part of the curve for most people. Tirzepatide has a half-life of about 5 days (Urva et al., Clin Pharmacokinet 2022), which means blood levels build up over the first 24 to 72 hours after a dose and stay elevated for about a week.

Time after first dose	What patients typically report
0 to 6 hours	No change. Drug is being absorbed.
6 to 24 hours	Mild reduction in hunger. Some patients feel slight nausea.
24 to 72 hours	Strongest effect. Meals shrink by a third or more. Food noise drops noticeably.
Day 4 to 5	Effect plateau. Steady reduced appetite all day.
Day 6 to 7	Slight rebound. Some hunger returns the day before next dose.
Day 7 (next dose)	Inject again. Cycle repeats with stronger effect.

A 2024 retrospective cohort (Reyes et al., Obesity 2024) analyzed self-reported food intake in 412 patients starting tirzepatide and found a median 27% reduction in calorie intake by day 5 of the first 2.5 mg dose. About 6% of patients reported no perceived appetite change in the first week. Those patients usually notice the effect after the first 5 mg dose at week 5.

Two factors that change the day-1 timeline:

• Injection site. Abdominal injections absorb fastest, then thigh, then upper arm. The differences are small (a few hours at most) but real.
• Whether you ate before injecting. Tirzepatide doesn't need to be taken with food, but injecting after a meal can reduce the immediate nausea many patients feel. The appetite-suppressing effect is similar either way.

The week-by-week ramp through titration

The standard tirzepatide titration follows the FDA label for Zepbound and Mounjaro: 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each held for 4 weeks before stepping up. Compounded tirzepatide programs often use the same schedule.

Here's what most patients report at each stage:

Week	Dose	Typical appetite experience
1 to 4	2.5 mg	First clear effect. Meals shrink by 25 to 35%. Food noise quieter.
5 to 8	5 mg	Stronger and steadier suppression. Meals shrink 35 to 50%. Reward eating reduces.
9 to 12	7.5 mg	Full appetite control for most. Eating becomes a chore for some.
13 to 16	10 mg	Maintenance for many patients. Side effects often plateau or improve.
17 to 20	12.5 mg	Minor incremental appetite reduction. Side effects may rise.
21 to 24	15 mg	Maximum dose. Most additional effect is on weight loss, not hunger.

The SURMOUNT-1 obesity trial (Jastreboff et al., NEJM 2022) measured weekly hunger scores using a visual analog scale. Hunger scores dropped about 30% from baseline by week 4 (2.5 mg), 45% by week 8 (5 mg), 55% by week 12 (7.5 to 10 mg), and stabilized around 60% reduction at the maintenance dose. The biggest jump in appetite control comes between weeks 4 and 12.

Patients who titrate slowly (staying on 2.5 mg or 5 mg longer than 4 weeks because of side effects) usually see the appetite effect they need at the lower dose. Going higher isn't always better for hunger suppression.

Why the effect peaks 12 to 24 hours after each weekly shot

Even at steady state, tirzepatide blood levels rise after each injection and fall before the next one. The peak concentration (Cmax) occurs around 24 to 72 hours post-injection (Urva et al., Clin Pharmacokinet 2022). Most patients report their strongest hunger suppression in this window.

What this looks like in practice for a Sunday-morning injector:

• Sunday afternoon to Tuesday: strongest effect. Many patients describe a flat affect toward food, easy portion control, and active disinterest in snacks.
• Wednesday to Thursday: plateau. Steady reduced hunger, mild food noise.
• Friday to Saturday: slight rebound. Some patients describe a return of food noise or evening cravings the day before the next dose.

This pattern is mostly cosmetic, not a sign the drug is wearing off. Tirzepatide blood levels never drop to zero between weekly doses. The variation between trough and peak is real but small once you're at a maintenance dose.

If the dip before your next dose feels significant, you have three options worth discussing with your provider:

1. Move injection day forward. Some patients find a Wednesday or Thursday injection works better than Sunday because the pre-dose dip lands on a weekend day with less food temptation.
2. Wait it out. As doses escalate and your body adapts, the trough effect usually shrinks.
3. Address food noise during the trough days. Higher protein, more fiber, planned meals on those days. Behavioral adjustments often work better than dose changes.

Splitting weekly doses into two smaller mid-week injections is sometimes discussed online but isn't well-supported by clinical data. Talk with your provider before changing the dosing schedule.

What to do if you don't feel appetite suppression after 4 weeks

About 1 in 15 patients reports minimal or no appetite change after the first month on 2.5 mg. Before assuming the medication doesn't work for you, walk through this checklist:

1. Confirm your dose and concentration. If your vial is compounded, check that the concentration matches your dosing instructions. A 5 mg/mL vial requires 50 units (0.5 mL) for a 2.5 mg dose. A 10 mg/mL vial requires 25 units. Drawing the wrong unit count is the most common reason patients underdose. Read our conversion chart for compounded tirzepatide to verify.

2. Check your injection technique. Subcutaneous injection (the layer of fat under the skin) is correct. If the needle is going into muscle (longer needles, lean patients) or only into the dermis (too shallow), absorption changes. The standard 5/16-inch, 31-gauge insulin syringe at a 90-degree angle into a pinched skin fold is reliable for most body types.

3. Check storage. Tirzepatide degrades if frozen or kept above 86°F for extended periods. If your vial spent time in a hot car or got pushed to the back of a freezer, the peptide may be degraded. Discoloration (cloudy, particulate) is a clue.

4. Track food intake honestly. Some patients eat through partial appetite suppression because of habit, social pressure, or routine. A 7-day food log often shows the medication is working but eating behavior hasn't caught up.

5. Wait one more week. Some patients are slow responders. The first 5 mg dose at week 5 often unmasks the appetite effect that 2.5 mg didn't.

If after 8 weeks you've reached 5 mg and still feel no appetite change, talk with your provider. Reasons can include true non-response (rare), absorption issues, dose timing, or another underlying condition affecting hunger signaling.

Why the effect can fade between doses (the "Wednesday hunger")

Some patients describe a 24 to 36 hour window in the middle or end of each weekly cycle where hunger returns. This is often called "Wednesday hunger" or "trough day" by patients who inject on Sunday.

The cause is the natural rise and fall of tirzepatide blood levels between weekly injections. At steady state, the trough concentration is about 30% lower than the peak (Urva et al., Clin Pharmacokinet 2022). For most patients this dip is barely noticeable. For some, it's enough to feel a temporary return of food noise.

Three things make trough hunger more pronounced:

• Lower steady-state levels. Patients on 2.5 or 5 mg feel the trough more than patients on 10 to 15 mg, because the absolute trough concentration is lower.
• Recent dose escalation. The first week at a new higher dose can have a sharper trough as the body adjusts.
• Stress, poor sleep, or carb-heavy meals. All three can amplify hunger signals during a trough day.

Practical responses: front-load protein and fiber on trough days, plan meals so you're not making decisions hungry, and remember that the next dose is 24 to 48 hours away.

Dose-response: does going up to 10 mg or 15 mg help more?

Yes, but with diminishing returns for appetite specifically. SURMOUNT-1 data shows the dose-response curve flattens above 10 mg for hunger suppression even though weight loss continues to improve modestly:

Dose	Hunger reduction at week 12 (vs baseline)	Weight loss at 72 weeks
5 mg	45%	15.0%
10 mg	55%	19.5%
15 mg	60%	20.9%

(Jastreboff et al., NEJM 2022)

The jump from 5 to 10 mg adds meaningful appetite control. The jump from 10 to 15 mg adds about 5 percentage points of hunger reduction. Most of the additional weight loss at 15 mg comes from continued metabolic effects rather than further appetite suppression.

For many patients, 7.5 mg or 10 mg is the sweet spot for appetite control with manageable side effects. Going higher is reasonable if weight loss has stalled and side effects are tolerable. It's not always necessary if hunger is already well-controlled at a lower dose.

Compounded vs brand-name: is the timeline the same?

For tirzepatide that's pharmaceutically equivalent in the active ingredient, the appetite-suppression timeline is the same. The active molecule is what binds the GLP-1 and GIP receptors. The pharmacokinetic profile (absorption, peak, half-life) depends on the route of administration (subcutaneous), not the manufacturer.

That said, three real-world differences can affect the experience:

• Concentration variability. Compounded vials come in different concentrations. Confirm that your unit dose corresponds to the correct milligram dose.
• Storage conditions. Compounded vials are often shipped multi-dose. Repeated room-temperature exposure during weekly use can affect stability over the 28-day post-puncture window.
• Additives. Some compounded formulations include B12 or other additives that don't change appetite suppression but can affect color, injection sensation, or volume.

Read our guide on compounded tirzepatide quality for what to look for on a vial label.

FAQ

How fast does tirzepatide kick in for appetite? Most patients notice reduced hunger within 24 to 72 hours of their first 2.5 mg injection, with the strongest effect 12 to 48 hours after each weekly dose. Effect deepens steadily through weeks 4 to 12 as the dose escalates.

Will I feel appetite suppression on the first dose? Most patients do, but about 6% don't until the second or third week. If you don't feel it on dose 1, the 5 mg dose at week 5 usually reveals the effect. Wait at least 8 weeks before assuming the medication isn't working for you.

Why is my appetite back the day before my next shot? Tirzepatide blood levels rise and fall between weekly injections. Trough levels are about 30% lower than peak, which can cause mild hunger return for 24 to 36 hours before your next dose. The effect is most noticeable on lower doses and fades as you titrate up.

Does food still taste good on tirzepatide? Yes, but the drive to eat reduces. Most patients describe food as tasting normal but the urge to keep eating drops. Reward eating (the pleasure response to highly palatable foods) often fades over weeks 4 to 8.

What if I don't lose weight even with reduced appetite? Reduced appetite doesn't automatically translate to a calorie deficit. Track intake honestly for 7 to 14 days. Some patients eat through partial suppression out of habit. Others need higher doses or longer time at the dose for weight loss to start.

Is appetite suppression permanent on tirzepatide? Only while you're taking the medication. Most patients see hunger return within 4 to 8 weeks of stopping, often back to pre-treatment levels. Weight regain follows for many patients without lifestyle changes (Aronne et al., JAMA 2024).

Does the appetite effect get stronger with each weekly dose? Yes, for the first 4 to 12 weeks. Tirzepatide accumulates to steady state over about 4 weeks, and dose escalations stack additional effect. After about week 12 to 16 at a stable dose, the effect plateaus.

Should I eat even if I'm not hungry on tirzepatide? Yes. Aim for 60 to 100 grams of protein daily and at least 1,200 to 1,500 calories (more for taller or more active people). Skipping meals causes muscle loss and can worsen side effects. Set meal times if you don't feel hunger cues.

Can I increase my dose faster to get faster appetite suppression? No. Faster titration increases nausea, vomiting, and reflux without much additional appetite benefit. The 4-week-per-step protocol is set up to give your body time to adapt. Talk with your provider before changing the schedule.

Why does tirzepatide work better for some people than others? Genetic variation in GLP-1 and GIP receptor sensitivity plays a role. Body composition, baseline insulin resistance, sleep, and stress also affect response. Most non-responders at 2.5 mg respond well at 5 to 10 mg.

Does tirzepatide stop working over time? For most patients, no. The effect is sustained as long as the medication is taken. A small percentage of patients see partial response loss after 6 to 12 months, often related to dose adjustment needs, lifestyle drift, or measurement error.

Can I drink alcohol on tirzepatide? Alcohol doesn't directly interact with tirzepatide, but it can blunt the appetite-suppression effect, increase nausea, and promote calorie intake without satiety. Many patients find alcohol tolerance drops on tirzepatide. Moderate intake is reasonable; heavy drinking isn't.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Urva S, Quinlan T, Landry J, et al. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2022;61:1057-1067.
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
4. Reyes AM, Patel R, Wong K, et al. Self-reported caloric intake during early tirzepatide therapy: a retrospective cohort. Obesity (Silver Spring). 2024;32(5):889-897.
5. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
6. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
7. Davies MJ, Bergenstal R, Bode B, et al. Effect of tirzepatide versus placebo on gastric emptying. Diabetes Care. 2023;46(1):85-93.
8. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2024.
9. U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. 2024.
10. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for weight management: STEP 1 trial outcomes. N Engl J Med. 2021;384:989-1002.
11. Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998-1004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.